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S U M M A R Y 
Respiratory disease remains an increasing global health burden, however few new 
medicines for asthma and chronic obstructive pulmonary disease (COPD) have 
reached the market in the past decade. Whilst there has been a considerable 
amount of research investment into the development of new inhaled medicines, 
many fail due to safety or efficacy.  One of the main reasons for this is the 
observation of a foamy alveolar macrophage responses in rats in pre-clinical 
studies which limits the dose of these compounds in subsequent studies despite 
not knowing if these observations are toxic in humans.  The ultimate aim of this 
work is to develop an accurate, immune responsive, human alveolar macrophage 
based co-culture model for the assessment of inhaled medicines. Accordingly, 
U937, a human lung-derived monocyte cell line, was differentiated to a 
macrophage phenotype in the presence of phorbol myristate acetate (PMA).  The 
activation, differentiation and functionality characteristics of native and treated 
cells were assessed using a combination of cell viability and morphological 
analyses, microarray technology, flow cytometry and phagocytic ability.  The 
concentration of PMA was found to have a more significant impact than 
incubation time on the expression of macrophage cell surface markers, 
morphology and viability.  
 
 
